News & Insights

AHA/ACC 2026 Guideline Updates – For Clinicians

At Ventegra, we recognize that clinicians are at the center of advancing meaningful, lasting health outcomes. As new 2026 guidance from the AHA/ACC continues to evolve, it reinforces a shared priority: earlier identification of risk, more precise intervention, and a sustained focus on prevention.

For clinicians, this shift represents an opportunity to move beyond episodic care toward proactive, longitudinal management of cardiovascular health—supported by data, aligned incentives, and evidence-based decision-making. Together, these advancements enable clinicians to deliver more personalized, efficient, and impactful care—improving outcomes today while protecting patient health for the future.

Primary Focus: Earlier, Personalized ASCVD Prevention

Earlier Risk Identification

ASCVD risk assessment is emphasized beginning in early adulthood (30s), with a shift toward lifetime risk reduction rather than reliance on 10-year risk alone.

PREVENT-ASCVD Risk Calculator

The PREVENT‑ASCVD calculator replaces pooled cohort equations. It applies to adults ages 30–79 and improves risk estimation across diverse populations.

Expanded Risk Stratification Tools For Select Individuals

Selective use of coronary artery calcium (CAC) scoring in men ≥40 years and women ≥45 years to refine ASCVD risk assessment and inform the intensity of LDL C and non HDL C treatment targets. Coronary artery calcium scoring is not always covered by insurance, including Medicare plans so verification of coverage is recommended. The test cost can range from $100 to $400.
One time lipoprotein(a) [Lp(a)] measurement in adulthood to identify individuals at increased ASCVD risk; elevated Lp(a) supports the need for more intensive LDL C lowering and aggressive management of additional risk factors.
Apolipoprotein B (ApoB) testing to assess residual atherogenic risk and guide therapy in patients who have achieved LDL C and non HDL C goals, particularly those with elevated triglycerides (>200 mg/dL), diabetes, or very low achieved LDL C (<70 mg/dL).

Updated LDL-C Targets

<100 mg/dL for borderline or intermediate‑risk patients
<70 mg/dL for high‑risk patients
<55 mg/dL for very high-risk patients

Guidance emphasizes lower cumulative LDL exposure across the lifespan.

Role of Nutrition and Physical Activity (Supportive)

Lifestyle interventions remain foundational. Heart-healthy nutrition and regular physical activity are reinforced as first-line interventions. Earlier risk identification expands the opportunity for effective non‑pharmacologic prevention.